Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects

Molecular Cancer

Volumn 8, Issue , 2009, Pages 91-

  Ivanova, Alla V ^a   Ivanov, Sergey V ^b   Prudkin, Ljudmila ^c   Nonaka, Daisuke ^b   Liu, Zhandong ^d   Tsao, Anne ^c   Wistuba, Ignacio ^c   Roth, Jack ^c   Pass, Harvey I ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN FUSI; PROTEIN TUSC2; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE LOCUS; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; PLEURA MESOTHELIOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TRANSCRIPTION REGULATION; UPREGULATION;

AMINO ACID SEQUENCE; ASBESTOS; CELL LINE, TUMOR; DOWN-REGULATION; FREE RADICAL SCAVENGERS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTOR-7; MESOTHELIOMA; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PLEURAL NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; REACTIVE OXYGEN SPECIES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 70749143916     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-91     Document Type: Article

References (45)

1. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008, 14:303-309. 10.1097/MCP.0b013e328302851d, 18520263.
2. Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis 2008, 3:34. 10.1186/1750-1172-3-34, 2652430, 19099560.
3. Miserocchi G, Sancini G, Mantegazza F, Chiappino G. Translocation pathways for inhaled asbestos fibers. Environ Health 2008, 7:4. 10.1186/1476-069X-7-4, 2265277, 18218073.
4. Ramalingam SS, Belani CP. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol 2008, 3:1056-1064. 10.1097/JTO.0b013e3181834f66, 18758312.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644. 10.1200/JCO.2003.11.136, 12860938.
6. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, Albelda SM. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004, 127:123-130. 10.1016/j.jtcvs.2003.08.034, 14752422.
7. Needham DJ, Lee JX, Beilharz MW. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 2006, 343:684-691. 10.1016/j.bbrc.2006.03.018, 16563349.
8. Rudge G, Barrett SP, Scott B, van Driel IR. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells. J Immunol 2007, 178:4089-4096.
9. Lerman MI, Glenn GM, Daniel L, Latif F, Hosoe S, Brauch H, Hampsch K, Delisio J, Orcutt M, Zbar B. A new polymorphic probe on chromosome 3p: lambda LIB28-77 (D3S169E). Nucleic Acids Res 1990, 18:205. 10.1093/nar/18.1.205-a, 330243, 1968621.
10. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000, 60:6116-6133.
11. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002, 21:6915-6935. 10.1038/sj.onc.1205835, 12362274.
12. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 20:1509-1518. 10.1038/sj.onc.1204175, 11313894.
13. Tischoff I, Markwarth A, Witzigmann H, Uhlmann D, Hauss J, Mirmohammadsadegh A, Wittekind C, Hengge UR, Tannapfel A. Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int J Cancer 2005, 115:684-689. 10.1002/ijc.20944, 15704097.
14. Senchenko V, Liu J, Braga E, Mazurenko N, Loginov W, Seryogin Y, Bazov I, Protopopov A, Kisseljov FL, Kashuba V. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene 2003, 22:2984-2992. 10.1038/sj.onc.1206429, 12771950.
15. Ivanova AV, Ivanov SV, Pascal V, Lumsden JM, Ward JM, Morris N, Tessarolo L, Anderson SK, Lerman MI. Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J Pathol 2007, 211:591-601. 10.1002/path.2146, 17318811.
16. Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson EN, Kondo M, Minna JD, Roth JA, Ji L. Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 2004, 64:2969-2976. 10.1158/0008-5472.CAN-03-3702, 15126327.
17. Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y, Yokota J, Kashuba V, Zabarovsky E, Kuzmin I. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 2001, 20:6258-6262. 10.1038/sj.onc.1204832, 11593436.
18. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 2002, 62:2715-2720.
19. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, Xu K, Atkinson EN, Bekele BN, Stephens LC. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004, 11:733-739. 10.1038/sj.cgt.7700756, 15486560.
20. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 2007, 26:6989-96. 10.1038/sj.onc.1210500, 17486070.
21. Deng WG, Kawashima H, Wu G, Jayachandran G, Xu K, Minna JD, Roth JA, Ji L. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res 2007, 67:709-717. 10.1158/0008-5472.CAN-06-3463, 17234782.
22. Deng WG, Wu G, Ueda K, Xu K, Roth JA, Ji L. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Cancer Gene Ther 2008, 15:29-39. 10.1038/sj.cgt.7701094, 17828283.
23. Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, Carbone M, Cruz C, Beck A, Webb C. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 2009, 124:589-599. 10.1002/ijc.23949, 18973227.
24. Lingjaerde OC, Baumbusch LO, Liestol K, Glad IK, Borresen-Dale AL. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics 2005, 21:821-822. 10.1093/bioinformatics/bti113, 15531610.
25. Shukla A, Gulumian M, Hei TK, Kamp D, Rahman Q, Mossman BT. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med 2003, 34:1117-1129. 10.1016/S0891-5849(03)00060-1, 12706492.
26. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, Mew DJ, Pogrebniak HW, Matthews WJ. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995, 59:835-844. 10.1016/0003-4975(95)00045-M, 7695406.
27. Webb CP, Pass HI. Translation research: from accurate diagnosis to appropriate treatment. J Transl Med 2004, 2:35. 10.1186/1479-5876-2-35, 524522, 15496233.
28. Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res 2009, 19:47-57. 10.1038/cr.2008.324, 19114989.
29. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 2006, 13:115-124. 10.1038/sj.cgt.7700896, 2455793, 16138117.
30. Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res 2008, 14:41-47. 10.1158/1078-0432.CCR-07-1252, 18172250.
31. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998, 63:854-865.
32. Ji L, Roth JA. Tumor suppressor FUS1 signaling pathway. J Thorac Oncol 2008, 3:327-330. 10.1097/JTO.0b013e31816bce65, 18379348.
33. Matin K, Salam MA, Akhter J, Hanada N, Senpuku H. Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice. Immunology 2002, 107:222-232. 10.1046/j.1365-2567.2002.01478.x, 1782793, 12383202.
34. Bai XF, Li O, Zhou Q, Zhang H, Joshi PS, Zheng X, Liu Y, Wang Y, Zheng P, Liu Y. CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J Exp Med 2004, 200:447-458. 10.1084/jem.20040131, 2211938, 15314074.
35. Wang L, Lin S, Rammohan KW, Liu Z, Liu JQ, Liu RH, Guinther N, Lima J, Zhou Q, Wang T. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet 2007, 3:e49. 10.1371/journal.pgen.0030049, 1847692,1847692, 17411341.
36. Liu Y, Zheng P. CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol 2007, 28:315-320. 10.1016/j.it.2007.05.001, 17531534.
37. Okazaki T, Wang J. PD-1/PD-L pathway and autoimmunity. Autoimmunity 2005, 38:353-357. 10.1080/08916930500124072, 16227150.
38. Dong H, Chen X. Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol 2006, 3:179-187. 2186063, 16893498.
39. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003, 81:281-287.
40. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005, 54:307-314. 10.1007/s00262-004-0593-x, 15599732.
41. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274. 10.1038/nrc1586, 15776005.
42. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006, 16:141-147. 10.1038/sj.cr.7310019, 16474426.
43. Sun Q, Sun L, Liu HH, Chen X, Seth RB, Forman J, Chen ZJ. The specific and essential role of MAVS in antiviral innate immune responses. Immunity 2006, 24:633-642. 10.1016/j.immuni.2006.04.004, 16713980.
44. Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res 2003, 13:2291-2305. 10.1101/gr.1349003, 403708, 12975311.
45. Ivanov SV, Salnikow K, Ivanova AV, Bai L, Lerman MI. Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene 2007, 26:802-812. 10.1038/sj.onc.1209842, 16878149.